Chronic eczema management

Reading File

Finding Sources

Reading File

Loading Image

I now have comprehensive content to deliver a thorough, well-structured answer on chronic eczema management.

Chronic Eczema (Atopic Dermatitis) Management

Chronic eczema/atopic dermatitis (AD) is managed through a proactive, stepwise strategy — not just reactive treatment of flares. The goal is to control subclinical inflammation, prevent recurrence, and modify overall disease course.

Management Plan Overview

Fig. 12.22 — Dermatology 2-Volume Set 5e

The three-tier framework (traffic-light model):

Tier	Action
Red (active disease)	Daily topical corticosteroid (TCS) of appropriate potency until clear (10 days–4 weeks); wet wraps for acute flares
Yellow (hot-spot maintenance)	Intermittent mid-potency TCS 2×/week and/or topical calcineurin inhibitor (TCI) 3–5×/week
Green (baseline — all patients)	Daily emollient to all skin + trigger avoidance

1. Patient Education

Education is a cornerstone of management and has been shown to improve outcomes. Key elements:

Disease mechanism, course, and triggers
Correct use of topical therapies
Goals of management (control, not cure)
Written action plans
Psychological support: cognitive-behavioral therapy, biofeedback, stress management

Resources such as structured "eczema school" programs and patient portals (e.g., nationaleczema.org) improve adherence.

— Dermatology 2-Volume Set 5e, p. 264

2. Skin Care Basics

Bathing: Lukewarm baths/showers followed immediately by moisturizer application ("soak and seal"). Harsh soaps should be avoided; gentle, fragrance-free cleansers preferred.

Emollients: Daily application of bland emollient cream or ointment to all skin — the foundation of all AD management regardless of disease activity.

Trigger avoidance: Common triggers include:

Irritants (soaps, detergents, wool, sweat)
Aeroallergens (dust mites, pet dander, pollens)
Foods (especially in children — eggs, milk, peanuts, wheat)
Stress, temperature extremes
Secondary infections (S. aureus, HSV)

3. Topical Anti-inflammatory Therapy

Topical Corticosteroids (TCS) — First-line

Potency selection is site- and severity-dependent:

Potency	Use
Class 1–2 (high)	Thick/lichenified plaques, nummular lesions, hands/feet
Class 3–4 (medium)	Moderate eczema in antecubital/popliteal fossae
Class 5–6 (low)	Mild eczema; face and skin folds

Apply daily until clear, then transition to maintenance (2×/week to the same "hot spots").

Topical Calcineurin Inhibitors (TCIs) — Steroid-sparing

Tacrolimus ointment (0.03% for children, 0.1% for adults) and pimecrolimus cream — particularly useful for face, eyelids, and intertriginous areas where steroids carry atrophy risk
Maintenance use 2–3×/week prevents flares without increasing total medication burden
Main side effect: transient local stinging/burning, which diminishes with continued use
No evidence of systemic immunosuppression; no confirmed cancer risk in clinical/post-marketing data (>15 years)

— Dermatology 2-Volume Set 5e

Crisaborole (PDE-4 inhibitor)

2% ointment, FDA-approved for mild-to-moderate AD ≥3 months of age
~30% achieve clear/almost clear skin after 4 weeks twice daily
Side effect: application-site stinging

Topical JAK Inhibitors

Ruxolitinib 1.5% cream (JAK1/2 inhibitor) — FDA-approved for short-term/non-continuous chronic treatment of mild-to-moderate AD in patients ≥12 years
50–55% achieve clear/almost clear skin at 8 weeks vs. 7–15% with vehicle
Maximum use: ≤60 g/week

4. Systemic Therapy (Moderate–Severe Disease)

Phototherapy: Narrowband UVB is first-line systemic option; PUVA for refractory cases.

Biologics:

Dupilumab (anti-IL-4Rα) — the most established biologic; blocks IL-4 and IL-13 signaling; approved for moderate-to-severe AD ≥6 months of age
Tralokinumab, lebrikizumab (anti-IL-13)
Increasingly used as maintenance therapy to reduce TCS dependence

Systemic JAK inhibitors (oral):

Upadacitinib, abrocitinib (JAK1-selective) — approved for moderate-to-severe AD in adults/adolescents; faster itch relief than dupilumab in head-to-head trials
Monitoring required: lipid panel, CBC, herpes zoster vaccination before initiation

Traditional immunosuppressants (second-line, off-label):

Cyclosporine (rapid onset, short-term use)
Methotrexate, azathioprine, mycophenolate mofetil (slower onset, longer-term options)
Systemic corticosteroids only for short bridging; avoid long-term use due to rebound flares

5. Managing Comorbidities and Complications

Secondary bacterial infection (S. aureus): topical mupirocin for localized; oral anti-staphylococcal antibiotics for widespread impetiginization
Eczema herpeticum (HSV superinfection): systemic acyclovir/valacyclovir — treat promptly, especially in children
Atopic march: screen for and co-manage asthma, allergic rhinitis, food allergy
Prurigo nodularis in severe chronic disease: dupilumab or nemolizumab

6. Special Subtypes Relevant to Chronic Eczema

Hand eczema: Alitretinoin (oral retinoid, not available in the US) can achieve complete or near-complete clearance in ~50% of chronic refractory cases — Andrews' Diseases of the Skin, p. 248
Nummular eczema: High-potency TCS; exclude contact allergy
Seborrheic dermatitis: Antifungal shampoos/creams (ketoconazole, ciclopirox), low-potency TCS

Summary Algorithm

All patients → Daily emollient + trigger avoidance
      ↓
Active flare → TCS (potency per site/severity) ± wet wraps
      ↓
Clearing → Step down to TCS 2×/week + TCI maintenance
      ↓
Inadequate control → Phototherapy → Biologics (dupilumab) or oral JAK inhibitors
      ↓
Severe/refractory → Specialist referral, cyclosporine bridging, clinical trials

The shift from reactive to proactive maintenance is the most important modern change in chronic eczema management — preventing sub-clinical inflammation between visible flares is as important as treating overt disease. — Dermatology 2-Volume Set 5e, p. 262

This is a shared conversation. Sign in to Orris to start your own chat.